Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 269 citing articles:

A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days
Xianming Liang, Qiu‐Yan Xu, Zhi-Juan Jia, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
Xiao‐Feng He, Jiao Su, Yunan Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
Samuel M. S. Cheng, Chris Ka Pun Mok, Karl CK Chan, et al.
Eurosurveillance (2022) Vol. 27, Iss. 18
Open Access | Times Cited: 34
Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
Jingjing Lv, Hui Wu, Junjie Xu, et al.
Infectious Diseases of Poverty (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 34
Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants
Krishna Mohan Vadrevu, Brunda Ganneru, Siddharth Reddy, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 32
Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis
Zejun Li, Shouhuan Liu, Fengming Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 32
Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
Haoyue Cheng, Zhicheng Peng, Shuting Si, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 798-798
Open Access | Times Cited: 31
Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021
Kun Xu, Chunxiang Fan, Yuxuan Han, et al.
International Immunology (2022) Vol. 34, Iss. 12, pp. 595-607
Open Access | Times Cited: 30
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
Yuemiao Zhang, Xupu Ma, Guanghong Yan, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101680-101680
Open Access | Times Cited: 30
Cost‐effectiveness of COVID‐19 vaccination: A systematic review
Yaqun Fu, Jingyu Zhao, Peien Han, et al.
Journal of Evidence-Based Medicine (2023) Vol. 16, Iss. 2, pp. 152-165
Open Access | Times Cited: 22
Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia
Eddy Fadlyana, Djatnika Setiabudi, Cissy B. Kartasasmita, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 5, pp. 545-555
Open Access | Times Cited: 20
Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial
Suad Hannawi, Lixin Yan, Linda Saf Eldin, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102195-102195
Open Access | Times Cited: 17
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial
Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, et al.
EBioMedicine (2022) Vol. 87, pp. 104386-104386
Open Access | Times Cited: 28
Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
Nando Reza Pratama, Ifan Ali Wafa, David Setyo Budi, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2180-2180
Open Access | Times Cited: 28
Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection
Samuel Cheng, Chris KP Mok, John KC Li, et al.
Journal of Clinical Virology (2022) Vol. 156, pp. 105273-105273
Open Access | Times Cited: 27
Effectiveness of COVID-19 Vaccine Booster Shot Compared with Non-Booster: A Meta-Analysis
Yajuan Zhu, Shuang Liu, Dingmei Zhang
Vaccines (2022) Vol. 10, Iss. 9, pp. 1396-1396
Open Access | Times Cited: 26
Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
Yaqun Fu, Jingyu Zhao, Wei Xia, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 25
Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials
Qianqian Xin, Qianhui Wu, Xinhua Chen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong
Runhong Zhou, Na Liu, Xin Li, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 32, pp. 100660-100660
Open Access | Times Cited: 24
Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults
Yuntao Zhang, Yunkai Yang, Q. L. Niu, et al.
Frontiers of Medicine (2022) Vol. 16, Iss. 1, pp. 93-101
Open Access | Times Cited: 23
Application of Traditional Vaccine Development Strategies to SARS-CoV-2
Halie M. Rando, Ronan Lordan, Alexandra Lee, et al.
mSystems (2023) Vol. 8, Iss. 2
Open Access | Times Cited: 14
Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study
Hong-Hong Liu, Yunbo Xie, Bao-Peng Yang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Vaccine development using artificial intelligence and machine learning: A review
Varun Asediya, Pranav Anjaria, R. A. Mathakiya, et al.
International Journal of Biological Macromolecules (2024), pp. 136643-136643
Closed Access | Times Cited: 6
Characteristics and clinical outcomes of patients with pre-delta, delta and omicron SARS-CoV-2 infection in Indonesia (2020–2023): a multicentre prospective cohort study
Anis Karuniawati, Ayodhia Pitaloka Pasaribu, L Gilbert, et al.
The Lancet Regional Health - Southeast Asia (2024) Vol. 22, pp. 100348-100348
Open Access | Times Cited: 5
Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences
Dorota Kamińska, Dominika Dęborska−Materkowska, Katarzyna Kościelska−Kasprzak, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1068-1068
Open Access | Times Cited: 22

Scroll to top